Amarin Q3 2026: Cost Cuts Flip the Company to Profit
As seen on the 24/7 Wall St. homepage on October 28, 2026.
The restructuring is now what drives Amarin: a 44% cut to operating expenses flipped it to net income of $245,000 from a year-ago loss, clearing the EPS consensus even as revenue missed expectations. Barclays is running a strategic review.
Continue ReadingShow less
Amarin returned to net income in Q3 2026 on expense discipline, not revenue growth, as total operating expenses fell 44% while the Recordati-linked global restructuring completed its course.
Revenue of $39.55 million fell year over year, missing expectations, as U.S. VASCEPA sales dropped under sustained generic pricing pressure. International demand offset part of that, with rest-of-world product revenue higher and European VAZKEPA demand climbing.
Sponsored
Amarin reported diluted EPS of $0.00, clearing the analyst consensus of negative $0.02. Management projects operating cash flow stays positive in Q4 2026, with cash holdings near $330 million by year-end.
CEO Aaron Berg confirmed the company is working with Barclays as its exclusive financial advisor on a strategic review aimed at maximizing shareholder value. Patent protection for VASCEPA and VAZKEPA runs through 2039 in European markets, and a Phase 3 trial at ESMO 2026 points to new applications in colorectal cancer. The range of outcomes from that review is wide.
Mentioned: AMRN